by Crestone, Inc. | Jun 7, 2021 | Press Releases
June 7, 2021 – Announcement: Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial for Novel Antibiotic CRS3123 to Treat C. difficile Infections. FDA also Grants CRS3123 ‘Qualified Infectious Disease Product’ (QIDP) and ‘Fast Track’ Designations. Learn...
by Crestone, Inc. | Jul 1, 2020 | Press Releases
July 1, 2020 – Announcement: Crestone, Inc. Secures NIH Funding for Development Through Phase 1 of Novel Antibiotic Candidate CRS0540, A Novel Inhibitor of DNA Replication in Gram-positive Pathogens. Learn More:...
by Crestone, Inc. | May 29, 2020 | Press Releases
May 29, 2020 – Announcement: Crestone, Inc. receives $250,000 Grant from State of Colorado Advanced Industries Accelerator program.
by Crestone, Inc. | Apr 27, 2020 | Press Releases
Apr 27, 2020 – Announcement: Crestone, Inc. Secures NIH Funding for Preclinical Development of Novel Antibiotic CRS3123 to Treat H. pylori Infections. Learn More:...
by Crestone, Inc. | Feb 13, 2020 | Press Releases
CFF Funding Secured Crestone, Inc. (Boulder) Secures CFF Funding for Preclinical Development of Novel Antibiotic to Treat NTM Infections. Learn More:...
